Navigation Links
HITRUST Confirms Release Date for First-Ever Common Security Framework for Electronic Health Information
Date:7/1/2008

Leaders From Healthcare, Professional Services, Information Security and

Liability Insurers Committed to Deliver a World-Class Framework

DALLAS, July 1 /PRNewswire/ -- The Health Information Trust Alliance (HITRUST) today announced that it is on target to deliver the first-ever Common Security Framework (CSF) by January 2009, thanks to the efforts of the leading health care organizations, professional services firms, information security specialists, liability insurers and other organizations that have joined together to actively participate in the HITRUST CSF program.

"The HITRUST CSF program is critical to effectively safeguarding electronic health information," said Daniel S. Nutkis, CEO, HITRUST. "As it is a substantial and complicated undertaking, we are very fortunate to have such capable, respected and committed organizations participating as part of our Drafting and Review Working Groups. I am amazed by the diversity and number of leading organizations with varying specialties participating in the HITRUST CSF program," Nutkis added.

"As one of HITRUST's founding organizations, I am very pleased to see that so many leaders in the industry have chosen to join us and support the development of a common security framework," said Jonathan Roberts, Senior Vice President and Chief Information Officer, CVS Caremark. "We at CVS Caremark have known for some time that the creation of the common security framework was a vital and missing component to effectively and efficiently protecting sensitive health information," Roberts added.

The HITRUST CSF is a comprehensive set of tools to aid organizations that create, store, access or exchange electronic health, financial, and other sensitive information in protecting their information assets and managing related risks, costs and complexities. The HITRUST CSF is comprised of three components -- an Information Security Implementation Manual, a Standards and Regulations Cross-Reference
'/>"/>

SOURCE Health Information Trust Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Air Methods Corporation Confirms Mid-Air Collision in Arizona
2. Pennsylvania Department of Health Confirms Fifth Salmonella Case Linked to National Outbreak
3. Perrigo Confirms Filing for Generic Version of VANOS(R)
4. Report confirms increased risk of smoking, substance abuse in bipolar adolescents
5. Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon
6. Pennsylvania Department of Health Confirms Rabid Kitten Found in Adams County
7. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
8. Air Methods Corporation Confirms Fatal Accident in Wisconsin
9. New Smoking Cessation Guideline Confirms That Now is the Time to Quit Smoking
10. Study by Texas A&M University-Corpus Christi Confirms Training With Vision Software Enhances Hitting Skills
11. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ers from the North Pole, Textsanta.net lets parent...a , North Pole, AK (PRWEB...cies at the North Pole Santa Claus has added SMS t...lobe informed of his Christmas progress at the Nor...tment have identified a large and growing percenta...
(Date:11/26/2009)...Ennis, P.A. is offering free nationwide confidenti... control pills who have suffered a Deep Vein Throm...ack or other related cardiac issues or had their G...800-856-6405 or go to the firm’s website at ...ase evaluation form. , (P...
(Date:11/25/2009)...swire/-SentinelleMedicalInc.,aleadingmanufacturero...algaryScientificInc.,aleadingproviderofsoftwareena...(TM)Breast4DAdvancedVisualizationsoftware. ,, T...tWebclientbasedmedicalimagingofferinginthemarket.C...-footprintaccess-requiringnosoftwaredownload,andru...
(Date:11/25/2009)...SNewswire/--TheBlackAIDSInstituterecentlyheldBoard...or2010. ,, ThenewBoardMembersareahighlydiverseg...ance,governmenthealthprograms,editorial,andbusines...fpersonalbackgroundsincludingbothheterosexualandga...epresentingmultipleagegroups. ,, (Photo: http:/...
(Date:11/25/2009)... statistically significant survival benefit from a...ceptor (ER)-positive tumors had high levels of pho...S118-P), according to a brief communication publis...onal Cancer Institute . , Approximately 50% of b...inical studies have shown that ER-alpha S118-P is ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
... human welfare, spread of infectious disease and f...atellite imagery in order to acquire the proper ba...in, the geography professor of Kansas State Univer... Doug Goodin uses remote sensing, in combinati...
...ate University, Doug Goodin, makes use of satellit...and cover //changes on human health and food secur...with other types of data, to monitor and predict t... Decisions about Human Welfare," which was sponsor...
... have been able to zero in (on) the modalities of ... and other types of diseases. // Clinical trials o...drug to reduce the potency of a key enzyme, in cha...nn Collegiate Professor of Chemistry at U-M. 'Ou...
...ecialist, NHS can be freed from its’ problems, if ..., are reconsidered before they are implemented. //...vatization plan may make matters worse for the dep...ce has deteriorated. Though plans of privatization...
... the launch of BARACLUDE? (entecavir) for the tre...llowing its approval by the Drug Controller Genera...ed for the treatment of chronic hepatitis B virus ...histologically active disease. BARACLUDE? is...
... are repeatedly failing to implement rules that wi...atients //from contaminated surgical instruments. ...keeping instruments in sets so they can be traced ...to see that surgical instruments were not contamin...
Other Medicine News:Health News:Ecological Changes affects human health, food security 2Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
(Date:11/25/2009)...a-FirstCall/--ChinaSkyOne,Medical,Inc.("ChinaSkyOn...ullyintegratedpharmaceuticalcompanydevelopingandpr...ofChina("PRC"),today,announcedthattheCompanyrecent...fPharmaceuticalandBiologicalProducts("ICPBP")exami...umanProstateSpecific,Antigen(ColloidalGold)anditsD...
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...G,November25/PRNewswire/--,iThembaPharmaceuticals,...ttheyhavesignedacollaborativeagreementtojointlymar...sscomputationalchemistryandleaddiscoveryexpertise,...medicinaland,syntheticchemistrysupporttoprojectsid...ThembaPharmaceuticalsandPyxisDiscovery,alsoannounc...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2AUDIO from Medialink and Guardian 3A Breast Cancer Awareness Month Highlights Need for Critical Illness Insurance 59684 1International SOS Awarded TRICARE Overseas Program Contract 59681 1International SOS Awarded TRICARE Overseas Program Contract 59681 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 1FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 2FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 3FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 4FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 5FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 6FDA Approves Elitek 28R 29 28rasburicase 29 for Management of Plasma Uric Acid Levels in Adults with Leukemia Lymphoma and Solid Tumors Receiving A 5545 7
...IRE)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (N...ase 3 trial of PRX-00023, a novel long-acting 5-HT...at the 47th Annual New,Clinical Drug Evaluation Un...ting is sponsored by the National Institutes of,He...armacology., The presentation highlighted data fro...
..., WA -- (MARKET WIRE) -- June 14,2007 -- Targeted...rting data from the dose escalation arm of the ong...nts with inflammatory,arthritis. Philip J. Mease, ...ington School of Medicine, chief of rheumatology,c...acticing,physician with Seattle Rheumatology Assoc...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 2Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 3Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 4Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 5Targeted Genetics Reports Inflammatory Arthritis Clinical Data at,European Rheumatology Conference 6
Anti-MPO - ELISA (P-ANCA)
Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA)
Iso-Insulin ELISA
RIDASCREEN Anti-RSV IgM Assay
Medicine Products: